UNIVERSITY OF MIAMI
Curriculum Vitae
Standard Format
1.
Date:
February 09, 2005
2.
Name:
Stephen P. Richman
4.
Office Phone: (305) 243-4909
6.
Current Academic Rank:
Professor
7.
Primary Department:
Department of Medicine
8.
Citizenship:
U.S.A.
9.
Visa Type (if non-citizen):
N/A
HIGHER EDUCATION
10. Institutional (institution; degree; date conferred):
June 1961 - June 1963 Stanford University, Palo Alto, California
June 1963 - June 1965 A.B. - Washington University, St. Louis, Missouri
June 1965 - June 1969 M.D. - Case Western Reserve University,
Cleveland, Ohio
11. Non-Institutional (description; dates):
N/A
12. Certification, licensure (description; board or agency; dates):
July 1970
National Board Medical Examiners
July 1972
American Board of Internal Medicine
October 1977 American Board of Internal Medicine - Medical Oncology
1
State Licenses
June 1970
July 1974
July 1980
June 1985
Pennsylvania
Texas
Kentucky
Florida
EXPERIENCE
13. Academic (institutions; rank/status; dates):
April 1999- July 2001
Acting Chief, Division of Hematology/Oncology
July 1985 - Present
Professor of Medicine, University of Miami School of Medicine
June 1969 - July 1970
Intern, Hospital University of Pennsylvania, Philadelphia,
Pennsylvania
June 1970 - July 1972
Resident, Medicine, Hospital University of Pennsylvania, Philadelphia, Pennsylvania
June 1972 - July 1974
Fellow in Oncology, Department of Developmental
Therapeutics, The University of Texas System Cancer Center,
M.D. Anderson Hospital and Tumor Institute, Houston, Texas
June 1974- July 1975
Faculty Associate, Department of Developmental Therapeutics, The University of Texas
System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Texas 77030.
June 1975 - July 1980
Assistant Professor of Medicine, Department of Developmental Therapeutics, The University of
Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Texas
77030
June 1976 - July 1980
Assistant Professor of Medicine, Department
of Medicine, The University of Texas Medical School
at Houston
June 1980 - July 1985 Associate Professor of Medicine, Department of Medicine, University of Louisville, Louisville,
Kentucky
June 1980 - July 1985
Associate Professor of Pharmacology, University of Louisville, Louisville, Kentucky
April 1983
Board of Trustees, Kentucky Chapter Leukemia Society of America, Inc.
1984
Principal Investigator, University of Louisville, Southeastern Cancer Study Group
2
June 1987- July 1992
Principal Investigator, University of Miami, Southwest Oncology Group
June 1985- July 1991
Chief, Division of Medical Oncology, Sylvester Comprehensive
Cancer Center
April 1989 - July 1991 Acting Chairman, Dept. of Oncology
March 1996- Present
Associate Director for Networks and Managed Care,
Sylvester Comprehensive Cancer Center
July 2000
Chairperson, Committee AA@, University of Miami IRB.
14. Non-Academic (employers; title; responsibilities; dates): N/A
15. Military (branch; rank; responsibilities; dates): N/A
PUBLICATIONS [author(s) (in actual precedence of authorship); title; publisher or journal name; date
(current year first); page numbers]
16. Books and monographs published:
N/A
17. Juried or refereed journal articles and exhibitions:
1.
Richman, S.P., et al: Studies of Vicia faba root meristems irradiated
with a negative pion beam. Rad. Res. Suppl. 7:283-289, l967.
2.
Izumi, A.K. and Richman, S.P.: Ectopic adrenocorticotropic hormone syndrome. Arch. Dermatol.
l02:555-559, l970.
3.
Richman, S.P., Mavligit, G.M., Wolk, R., Gutterman, J.U. and Hersh, E.M.: Epilesional
scarification: Preliminary report on a new approach to local immunotherapy. JAMA 234:1233-1235,
l975.
4.
Gercovich, F.G., Richman, S.P. Rodriguez, V., Luna, M., McCredie, K.B., and Brodey, G.P.:
Successful control of systemic Aspergillus niger infections in two patients with acute leukemia.
Cancer 36:2271-2276, l975.
5.
Hersh, E.M., Gutterman, J.U., Mavligit, G.M., Reed, R.C., and Richman, S.P.: BCG vaccine and
its derivatives. Potential practical considerations and precautions in human cancer immunotherapy.
JAMA 235:646-650, l976.
6.
Richman, S.P., Livingston, R.B., Gutterman, J.U., Suen, J.Y. and
Chemotherapy versus chemoimmunotherapy of head and neck cancer:
randomized study. Cancer Treat. Rep. 60:535-539, l976.
3
Hersh, E.M.:
Report of a
7.
Rodriguez, V., Richman, S.P., Benjamin, R.S., et al.: Phase II study with Baker's antifol in
solid tumors. Cancer Res. 37:980-983, l977.
8.
Richman, S.P., Gutterman, J.U., Hersh, E.M. and Mavligit, G. M.: Phase I study of
immunotherapy with methanol extraction residue of BCG (MER). Cancer Treat. Repts.
6l:47l-471, l977
9.
Schwarz, M.A., Gutterman, J.U., Hersh, E.M., Richman, S.P. and Mavligit, G.M.:
Immunotherapy and chemoimmunotherapy of malignant disease with BCG and
nonviable mycobacterial fractions. World J Surg. l:555-583, l977.
10. Suen, J.Y., Richman, S.P., Livingston, R.L., Hersh, E.M., Craig, R. and Tonymon, K.:
Results of the BCG adjuvant immunotherapy in l00 patients with epidermoid carcinoma
of the head and neck. Am. J. Surg. l34:474-478, l977.
11. Hortobagyi, G.N., Richman, S.P. Dandridge, K., Gutterman, J.U., Blumenschein, D.R.
and Hersh, E.M.: Immunotherapy with BCG administration by scarification. Standardization
of reactions and managements of side effects. Cancer 42:2293-2303, l978.
12. Hortobagyi, G.N., Gutterman, J.U., Snyder, R.O., Richman, S.P. and Hersh, E.M.: Pseudomonas
vaccine: A phase I evaluation for cancer research. Cancer Immunology and Immunotherapy
4:20l-207, l978.
13. Richman, S.P., Gutterman, J.U., Hersh, E.M. and Ribi, E.E.: Phase I-II study of intratumor
immunotherapy with BCG cell wall skeleton plus P3. Cancer Immunology and Immunotherapy
5:4l-44, l978.
14. Issell, B.F., Valdevieso, M., Hersh, E.M., Richman, S.P., Gutterman, J.U. and Bodey, G.P.:
Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer Treat
Rep. 62:1059-1063, l978.
15. Richman, S.P., Gutterman,J.U. and Hersh, E.M.: Cancer Immunotherapy. Canadian Medical Assoc. J.
120:322-329, l979.
16. Hortobagyi, G.N., Gutterman, J.U., Blumenschein, G.R., Tashima, C.K., Burgess, M.A., Einhorn, L.,
Buzdar, A.U., Richman, S.P. and Hersh, E.M.: Combination chemotherapy of metastatic breast
cancer with 5-fluorouracil, Adriamycin and Cyclophosphamide, and BCG. Cancer 43:1225-1233,
l979.
17. Blumenschein, G.R., Hortobagyi, G.N., Richman, S.P. et al: Alternating noncross resistant
combination chemotherapy and active non-specific immunotherapy with BCG or MER-BCG
for advanced breast carcinoma. Cancer 45:742-749, l980.
18. Maroun, J.A., Quesada, J., Hersh, E.M., Gutterman, J.U., Richman, S.P. et al.: A phase I toxicity
study of methanol extraction residue (MER) of Bacillus Calmette Guerin by intervenous route.
4
Cancer Treat. Rep. 63:1781-1786, l979.
19. Richman, S.P., Gutterman, J.U. and Hersh, E.M.: Chemotherapy and Immunotherapy of
malignant melanoma. Compreh. Ther. 6:57-6l, l980.
20. Richman, S., Chism, V.T. and Murphy, S.G.: Effect of microbial fractions and vehicle on
the survival of mice beating the Lewis lung carcinoma. Cancer Treat. Rep. 64:13291333, l980.
21.
Richman, S.P., Hersh, E.M., Gutterman, J.U., Rios, A., Hortobagyi, G.N., Blumenschein, G.R.
and Rib, E.E.: Administration of BCG cell wall skeleton into malignant effusions. Toxic and
therapeutic effects. Cancer Treat. Rep. 65:383-387, l98l.
22. Richman, S.P., Chism, V.T. and Murphy, S.G.: Augmentation of ADCC in mice by microbial
fractions. Cancer Immunol. Immunother. 11:233-238, l981.
23. Valdivieso, M., Richman, S., Burgess, A.M. et al.: Initial clinical studies of vindesine. Cancer
Treat. Rep. 65:873-875, l98l.
24. Feun, L.G., Jordan, G., Burgess, M.A., Hersh, E.M., Mavligit, G., McBride, C.M., Benjamin, R.S.
and Richman, S.P., et al.: The Natural History of Resectable Metastatic Melanoma
(Stage IVA Melanoma). Cancer 50:1656-1663, l982.
25. Blijham, G.H., Barlogie, B. and Richman, S. Et al: Medulloblastoma and neuroblastoma in adults.
Neth. J. Med. 25 (4):94-99, l982.
26. Woodcock, T.M., Blumenreich, M.S., Richman, S.P. Kubota, T.T., Gentile, P.S. and Allegra, J.C.:
Combination Chemotherapy with Cis-Diamminedichloroplatinum and Vinblastine in Advanced
Non-Small Cell Lung Cancer. J. Clin. Oncol. l:247-250, l983.
27. Allegra, J.C., Woodcock, T.M., Richman, S.P., Bland, K.I. and Witliff, J.L.: A Phase II Trial
of Tamoxifen, Premarin, Methotrexate and 5-Fluorouracil in Metastatic Breast Cancer.
Breast Cancer Treat. and Res. 2:93-99, l982.
28. Richman, S.P., Woodcock, T. M., Kubota, T.T., Blumenreich, M.S., Gentile, P.S. and Allegra J.C.:
A Phase II Trial of Vinblastine, Bleomycin and Cisplatin (VBP) Followed by Decarbazine and
Mitolactol in Metastatic Melanoma. Cancer Treat. Repts. 68:l395-l396, l984.
29. Blumenreich, M.S., Woodcock, T.M., Jones, M., Richman, S.P. et al.: High dose cisdiamminedichloroplatinum II in patients with advanced malignancies. Cancer 55:1118-1122, 1985.
30. Blumenreich, M.S., Woodcock, T.M., Richman, S.P, et al.: A Phase I trial of Dactinomycin
intravenous infusion in patients with advanced malignancies. Cancer 56:256-258, l985.
31. Blumenreich, M.S., Woodcock, T.M., Gentile, P.S., Barnes, G.R., Jose, B., Sherrill, E.J., Richman,
5
S.P., et al. High-Dose cisplatin and vinblastine infusion with or without radiation therapy in patients
with advanced non-small cell lung cancer. J. Clin. Oncol. 5:l725-l730, l987.
32. Sridhar, K.S., Bounassi M.J., Raub, W., and Richman, S.P.: Clinical features of adenosquamous
lung carcinoma in 127 patients. Am. Rev. Respir. Dis. 142:19-23, 1990.
33. Sridhar, K.S., Samy, T.S.A., Agarwal, R.P., Duncan, R.C., Benedetto, P., Krishan, A.G., Vogel,
C.L., Feun, L.G., Savaraj,N.M., Richman,S.P. and Zubrod, C.G. A Phase I study
of 4'-0-Tetrahydropyranyladriamycin. Cancer 66:2082-2091, 1990.
34. Feun, L.G., Savaraj, N., Benedetto, P., Hanlon, J., Sridhar, K.S., Collier, M., Richman, S., Liao,
S.H., and Clendennin, N.J. Phase I trial of piritrexim capsules using prolonged, low-dose oral
administration for the treatment of advanced malignancies. J.Natl. Cancer Inst. 83: 51-55, 1991.
35. Ardalan, B, Chua, L., Tian, E., Reddy, R., Sridhar, K.S., Benedetto, P., Richman, S. et al.
A Phase II study of weekly 24 hour infusion with high-dose Fluorouracil with Leucovorin in
colorectal carcinoma. J. Clin Oncol 9: 625-630, l99l.
36. Sridhar, K., Hussein, A., Benedetto, P., Waldman, S., Feun, L., Savaraj, N., and Richman S.
Phase II Trial of Mitoxantrone in Head and Neck Carcinoma. Am. J. Clin. Oncol.
14:298-304, 1991.
37. Ardalan, B., Sridhar K.S., Benedetto, P., Richman, S., Waldman, S., Morrell, L., Feun, L., Savaraj, N.,
Fodor, M., Livingstone, A. A Phase I, II Study of High Dose 5-Fluorouracil and High Dose Leucovorin
with Low Dose Phosphonacetyl-L-Aspartic Acid in Patients with Advanced Malignancies. Cancer
68:1242-1246, 1991.
38. Sridhar K.S., Raub, Jr., W., Duncan R.C., Hilsenbeck S., and Richman S.P. Lung carcinoma in
1,336 patients. Am. J. Clin. Oncol. 14:496-508, 1991.
39. Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE,
Siegel R and VandePol CJ. Comparative study of pamidronate disodium and etidronate disodium in
the treatment of cancer-related hypercalcemia. J. Clin. Oncol. 10:134-142, 1992.
40. Ardalan, B., Sridhar, K., Reddy, R., Benedetto, P., Richman, S., Waldman, S., Morrell, L., Feun, L.,
Savaraj, N., and Livingstone, A. Phase I study of high dose 5-fluorouracil and high dose leucovorin
with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Int. J.
Radiation Oncology Biol. Phys. 22: 511-514, 1992.
41. Ardalan B., Ucar A., Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K.
Phase I trial of low dose N-Phosphonacetyl-L-Aspartic Acid and High dose
5-Fluorouracil administered concomitantly with Radiation Therapy for Unresectable Localized
Adenocarcinoma of the Pancreas. Cancer, 74:7, 1994.
42. Hantel, A., Tangen, C.M., Macdonald, J.S., Richman, S.P. et al. Phase II trial of
6
trimetrexate in untreated advanced gastric carcinoma. Invest. New Drug 12:155-157, 1994.
43. Feun L.G., Savaraj, N., Moffat, F., Robinson, D., Liebmann, A., Hurley J., Raub, Jr.,W.A. and
Richman, S.P. Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC, and
tamoxifen in advanced malignant melanoma. Melanoma Res. 5: 273-276, 1995.
44. Whitehead R.P., Wolf, M.K., Solanski, D.L., Hemstreet, G.P., Benedetto, P., Richman, S.P. et al.
A phase II trial of continuous infusion recombinant interleukin-2 in patients with advanced renal
cell carcinoma: A Southwest Oncology Group Study. J. Immunotherapy 18: 104-114, 1995.
45. Martino, R.L., Fleming, T.R., Morrell, L.M., Ardalan,B., Richman, S.P.,
and Macdonald, J.S. Phase II trial of low dose N-(phosphonacetyl)-disodium-L-aspartic acid and
high-dose
24-hour
infusional
5-Fluorouracil
in
advanced
gastric
adenocarcinoma.
A Southwest Oncology Group Study.Invest. New Drugs 14:419-421, 1996.
46. Morrell, L.E., Lee, Y.J., Hurley, J., Arias, M., Mies,C., Richman, S.P., Hernandez, H., Donofrio,
K., Raub, Jr.,W.A., and Cassileth, P.A.
A phase II trial of neoadjuvant methotrexate,
vinblastine,doxorubicin, and cisplatinum in the treatment of patients with locally advanced
breast carcinoma.Cancer 82:503-511, 1998.
47. Anderson, K.O. Mendoza, T.R., Valero, V., Richman, S.P., et al. Minority Cancer Patients and their
Providers. Pain management attitudes and practice. Cancer 88:1929-1938, 2000.
48. Anderson, K.O., Richman,S.R., Hurley, J., et. al. Cancer pain management among minority patients: Perceived
needs and barriers to optimal control. Submitted to cancer
ABSTRACTS
1.
Richman, S.P.: Phase I study of Immunotherapy with methanol extraction residue of
BCG (MER). Proc. Amer. Soc. Clin. Oncol. l6:l025, l975.
2.
Rodriguez, V., Richman, S. P., Benjamin, R.S. et al.:
Amer. Assoc. Cancer Res. l7:60, l976.
3.
Richman, S.P., Gutterman, J.U., Hersh, E.M. and Price, H.R.:
Phase I study of intratumor
immunotherapy with BCG cell wall skeleton plus P3. Proc. Amer. Soc. Clin. Oncol.
l8:35l, l977.
4.
Richman, S. P., Murphy, S., Hersh, E.M., Gutterman, J.U. and Ribi, E.: Toxicity in mice
of BCG wall skeleton, trehalose dimycolate and mutant endotoxin attached to oil
droplets. AFCR 26:36A, 1978.
5.
Richman, S.P., Hortobagyi, G.N., Gutterman, J.U., Hersh, E.M., Mavligit, G. and Dale, S.:
Toxicity of BCG administered by scarification to cancer patients. Am. Soc. Clin. Oncol.
l9:449, l978.
7
Phase II studies of Baker's antifol. Proc.
6.
Richman, S.P., Chism, V. and Murphy,S.: Vehicle and microbial fractions interact to prolong survival
of mice with Lewis lung carcinoma. Amer. Assoc. Cancer Res. 20:l44, l979.
7.
Murphy, S., Richman, S., and Hersh, E.: Immunological unresponsiveness in treated
leukemic guinea pigs. Amer. Assoc. Cancer Res. 20:l70, l979.
8.
Richman, S.P., Hortobagyi, G.N., Legha, S.S., et al.: Prognostic significance of pleural effusion
patients with metastatic breast carcinoma treated with systemic chemotherapy. Proc. Amer. Assoc.
Res. 2l:l70, l980.
9.
Allegra, J.C., Woodcock, T.M., Richman, S.P., Patel, J.D. and Wittliff, J.L.: A Phase II Evaluation
of Tamoxifen, Premarin, Methotrexate (MTX) and 5-Fluorouracil (5-FU) in Stage IV Breast Cancer.
Am. Soc. Clin. Oncol. 22:44l, l980.
10. Woodcock, T.M., Allegra, J.C., Richman, S.P., Horowitz, J.A., and Snider, H.L.: A Phase II
Evaluation of Vinblastine (VLB) and Diamminedichloroplatinum II (DDP) in Non-Small Cell Cancer
of the Lung. Am. Soc. Clin. Oncol. 22:50l, l98l
11. Richman, S.P., Tatum, K. and Richman, K. (SPON: William J. Waddell): Monocyte Cytotoxicity
Assay in Normal Donors. American Society of Pharmacology and Experimental Therapeutics
and the Society of Toxicology, May, l982.
12. Richman, S.P., Woodcock, T.M., Lalley, K., Tatum, K., and Spalding, S: Doxorubicin Concentrations in
Human Mononuclear Cells Following Therapy. Am. Soc. of Clin. Oncol., December, l982.
13. Richman, S.P., Tatum, K., Stadig, B., and Richman, K.: Ammonia Exposure In Vitro Depresses
Monocyte Cytotoxicity. Am. Assoc. for Cancer Res., December, l982.
14. Richman, S.P., Woodcock, T. M., Lalley, K. et al.: Doxorubicin Concentrations in
Human Mononuclear Cells Following Therapy. Proceeding A.S.C.O. 2:247-250, l983.
15. Richman, S.P., Tatum, K., Stadig, B., et al.: Ammonia Exposure In Vitro Depresses Monocyte
Cytotoxicity. Proceeding A.A.C.R. 24:2l0, l983.
16. Blumenreich, M.S., Woodcock, T.M., Jones, M.K., Richman, S.P., Gentile, P.S., Kubota, T.T.
and Allegra, J.C.: High-Dose Cisplatin (DDP) in Patients (PTS) with Advanced Malignancies.
Proc. Am. Assoc. for Clin. Res. May, l984.
17. Blumenreich, M.S., Woodcock, T.M., Richman, S.P., Gentile, P.S., Kubota, T.T., Greenwell,
S.K., Jones, M.K. and Allegra, J.C.: High-Dose Cisplatin (DDP) and Vinblastine (VLB)
Infusion in Advanced Non-Small Cell Lung Cancer (NSCLC). Proc. Am. Soc. of Clin. Oncol. 3:23l,
1984.
18. Richman, S.P., Lopez-Bernstein, G., Woodcock, T.M., Lalley, K. and Perez-Soler, R.:
8
in
Cancer
Pharmacology of Doxorubicin Uptake into Human Monocytes In Vitro. Proc. Am. Assoc. of
Cancer Res. 25:163, l984.
19. Woodcock, T.M., Allegra, J.C., Richman, S.P., Blumenreich, M.S., Kubota, T.T., Gentile,
P.S., Lalley, K.A., Jones, M.K., Greenwell, S.K.: Pharmacology and Phase I Trial of Weekly
Daunorubicin (DNR). Proc. Am. Soc. of Clin. Oncol. 3:42, l984.
20. Fischl, M., Lucas, S., Richman, S., Koch, G.: Phase II study of Wellferon and Vincristine
in AIDS related Kaposi's sarcoma. Proc. Am. Soc. Onc. 6:2, l987.
21. Feun, L., Clendenin, N.J., Savaraj, N., Benedetto, P., Sridhar, K., Hanlon, J., Collier, M.,
and Richman, S. Phase I trial of Piritrexim capsules using prolonged low dose administration.
Pro. AACR, l988.
22. Richman, S.P., Smith, D., Hilsenbeck, S., and East, D.: Review of Cases of Breast Carcinoma
at University of Miami/Jackson Memorial Hospital. American Cancer Society, Florida Division:
Proc. Twelfth Annual Cancer Research Seminar for the Researchers of Florida, Abstract #27, 1989.
23. Hussein, A., Ardalan, B., Shanahan, W., Aspinall, R., Gardiner, P.,Shield, M., Richman,
S., Benedetto, P., Feun, L., Waldman, S.,Glantz, A., Sklaver,L., and Sridhar, K.: Phase I
Continuous (Cont.) Intravenous (IV) Infusion of Carbetimer (CBT) in Refractory Malignancies.
American Cancer Society, Florida Division: Proc. Twelfth Annual Cancer Research Seminar for
the Researchers of Florida, Abstract #31, 1989.
24. Hussein, A., Ardalan, B., Sklaver, L., Reddy, R., Savaraj, N.,Waldman, S., Richman, S.,
Feun, L., Hung, S., Benedetto, P., and Sridhar, K.: Chemotherapy (C) of Advanced Carcinomas
(Ca) with 5-Fluorouracil and Leucovorin (LV). American Cancer Society, Florida Division: Proc.
Twelfth Annual Cancer Research Seminar for the Researchers of Florida, Abstract #35, 1989.
25. Hung, S., Savaraj, N., Reddy, R., Jeffers, L., Schiff, E., Waldman, S.,and Richman, S.:
Tamoxifen in the Treatment of Hepatocellular Carcinoma (HCC). Proceedings of the
American Cancer Society, Florida Division: Proc. Twelfth Annual Cancer Research Seminar
for the Researchers of Florida, Abstract #428, 1989.
26. Hung, S., Savaraj, N., Reddy, R., Jeffers, L., Schiff, E., Waldman, S., and Richman, S.:
Tamoxifen in the Treatment of Hepatocellular Carcinoma (HCC). Proc. Am. Soc. of Clin.
Oncol. 8:ll0, l989.
27. Ardalan, B., Hussein, A., Sklaver, L., Reddy, R., Benedetto, P., Sridhar, K., Richman, S.,
Feun, L., Savaraj, N., Waldman, S., and Hung, S.: Chemotherapy (C) of Advanced Carcinoma
(Ca) with 5-Fluorouracil (FU) and Leucovorin (LV). Proc. Am. Soc. of Clin. Oncol. 8:ll6, l989.
28. Sridhar, K., Hussein, A., Barmann, A., Benedetto, P., Ardalan, B., Waldman, S., Richman,
S., Feun, L., Savaraj, N., Morrell, L., and Donnelly, E.: Phase II Study of Q3 Week IV Bolus
Pirarubicin (4'-0-Tetrahydropyranyladriamycin) in Head and Neck Carcinoma (H & N Ca). Proc.
9
Am. Soc. of Clin.Oncol. 9:179, 1990.
29. Waldman, S., Sridhar, K., Richman, S., East D., Berlin, N., Vogel, C., Salewski, E.: Phase II
Trial of Pirarubicin (P) in Advanced Breast Ca (BC). Proc. Am. Soc. of Clin. Oncol. 9:50, 1990.
30. Chua, L., Ardalan, B., Sridhar, K.S., Hussein, A., Richman, S. et al. A Phase II Study of
Short Term Protracted Infusion with High Dose 5-Fluorouracil with Leucovorin in
Colorectal Carcinoma. Proc. ASCO 9:104, 1990.
31. Morrell, L., Ardalan, B., Richman, S., et al. A phase II Study of Thiotepa in Combination
with 5-fluorouracil and Leucovorin in Patients with Advanced Breast Cancer. Proc. of ASCO 10:
62, 1991.
32. Sridhar, K.S., Krishan A., Anac, S., Duncan, R., Benedetto, P., Ardalan, B., Samy,T., Feun, L.,
Savaraj, and Richman, S. Phase I Study of Doxorubicin plus Prochlorperazine as a Resistance
Modifiere. Proc. ASCO 10: 106, 1991.
33. Ardalan, B., Sridhar, K., Richman, S., et al. Addition of HJigh Dose Leucovorin to High
Dose Infusion of 5-fluorouracil and Low Dose PALA: Effective in Pancreatic Cancer
Therapy. Proc. ASCO 10: 139, 1991.
34. Sridhar, K.S., Raub, Jr., W.A., Smith, D., and Richman, S. Lung Cancer: Recent Trends in
Smoking History in Lung Cancer Patients. Proc. ASCO 10: 249, 1991.
35. Flores M.R., Cassileth, P., Pozo, C., Sumrall E., Bean, J., Morrell, L., Hurley J., Love, N.,
Trapido, E., Richman, S. Assessment ofsocioeconomic, cultural health care diversity and
patient characteristics in breast cancer patients: an interim analysis. Proc ASCO 13: 454, 1994.
36. Ardalan, B., Ucar, A., Reddy, R., Livingstone, A., Schwade, J., Markoe, A., Richman, S.
Phase I trial of low dose PALA and high dose 5-fluorouracil (5-FU) as a short-term
infusion concomitantly with radiation therapy in the treatment of adenocarcinoma of the
pancreas.
37. Ardalan, B., Donofrio, K., Livingstone, A., Reddy, R., Richman, S. et al. A phase II study of
weekly low dose bolus phosphonacetyl-L-aspartic acid (PALA) and 24 hr infusion with high
dose fluorouracil (FU) with leucovorin (LV) in colorectal cancer. Proc. ASCO 14:220, 1995.
38. Morrell, L.E., Lee, Y.J., Hurley, J., Arias, M., Richman, S.P., Cassileth,P.A. Phase II Trial of
methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of locally advanced breast cancer.
Proc ASCO 16:643, 1997.
39. Ardalan, B., Sparling, L., Livingstone, A., Francheschi, D., Sridhar, K.S., Feun, L.G.,
Richman, S.P., Triplett, N. Phase II trial of high-dose 24-hour Infusion of 5-fluorodeoxyuridine
in patients with inoperable pancreatic cancer (previously failed 5-FU and Gemsar).Proc.
ASCO 16 999, 1997
10
18. Other works and publications:
1.
Gutterman, J.U., Mavligit, C.M., Reed, R.C., Richman, S.P., McBride, C.M. and Hersh, E.M.:
Immunology and immunotherapy of malignant melanoma: Historic review and perspectives for
the future. Sem. Onc. 2:l55-l84, l975.
2. Hersh, E.M., Mavligit, G.M. Gutterman, J.U. and Richman, S.P.: Immunotherapy of human cancer.
In: Cancer, A Comprehensive Treatise F.F. Becker, Editor, pp. 425-532, Plenum Press, New York, l977.
3.
Gutterman, J.U., Mavligit G.M. McBride, G.M., Richman, S.P., Burgess, M.A. and
Hersh, E.M.: Postoperative immunotherapy for recurrent melanoma: An updated report.
In: Immunotherapy of Cancer: Present Status of Trials in Man. Raven Press, New York
35-56, l977.
4.
Gutterman, J.U., Mavligit, G. M., Richman, S.P., Burgess, M.A. and Hersh, E.M.:
Chemoimmunotherapy of disseminated malignant melanoma with BCG: Followup
report. In: Immunotherapy of Cancer: Present Status of Trials in Man. Raven Press, New York,
l03-ll2, l977.
5.
Hortobagyi, G.N., Gutterman, J.U., Blumenschein, G.R., Buzdar, A., Burgess, M.A.,
Richman, S.P., Tashima, C.K., Schwarz, M. and Hersh, E.M.: Chemoimmunotherapy of Advanced
Breast Cancer with BCG. In: Immunotherapy of Cancer: Present Status of Trials in Man. New York,
Raven Press, l977, pp. 655-663.
6.
Hortobagyi, G.N., Gutterman, J.U., Blumenschein, G.R., Buzdar, A.U., Richman, S.P., Wiseman,
and C. and Herseh, E.M.: Immunotherapy and chemotherapy for human breast cancer. In:
Immunotherapy of Cancer: Present Status of Trials in Man. Raven Press, New York, 32l-345, 1978.
7.
Gutterman, J.U., Mavligit, G.M. and Richman, S.P. et al.: Immunotherapy for malignant melanoma.
In: Immunotherapy of Human Cancer. Raven Press, New York, 257-265.
8.
Gutterman, J.U., Richman, S.P., McBride, C.M. et al.: Immunotherapy for recurrent malignant
melanoma: Efficacy of BCG in prolonging the postoperative disease-free interval and survival. In:
Recent Results Cancer Research 68:359-362, l979.
9.
Richman, S.P., Gutterman, J.U., Hersh, E.M. and Mavligit, G.M.: Immunotherapy of cancer in man.
CRC Press for Handbook in Clinical Laboratory Science 335-363, l979.
10. Richman, S.P., Hersh, E.M., Gutterman, J.U. and Mavligit, G.M.: Immune depression in cancer
patients: Cell-mediated immunity. CRC Press for Handbook in Clinical Laboratory Science
379-404, l979.
11. Hortobagyi, G.N., Gutterman, J.U., Blumenschein, G.R., Buzdar, A., Burgess, M.A, Richman,
S.P., Tashima, C.K., Schwartz, M. and Hersh, E.M.: Chemoimmunotherapy of advanced breast
cancer with BCG. In: Recent Results in Cancer Research. 62:143-150, l979.
11
12. Richman, S.P., Hersh, E.M., Gutterman, J.U. et al.: Phase I-II Study of immunotherapy of
malignant effusions with BCG cell wall skeleton-P3. The Fifth Chicago Symposium.
Cancer Immunology Experimental and Clinical. Crispen (Ed.) Elsevier North Holland, Inc.,
473-479, l980.
13. Woodcock, T.M., Allegra, J.C., Richman, S.P., Lalley, K., Kubato, T.T., Blumenreich, M.S., Gentile,
P., Jones, M. and Seeger, J.: Pharmacology and Phase I Clinical Studies of Daunorubicin in Patients
with Advanced Malignancies. Seminars in Oncology ll:28-32, l984.
14. Seeger, J., Richman, S.P., Allegra, J.C.: Systemic therapy of malignant melanoma.
Med. Clin. N. Amer. 70:89-94, l986.
15. Richman, S.P. and Vogel, C.L. Kaposi's sarcoma in Current Therapy in Hematology-Oncology-3.
Brain, M.C. and Carbone, P. P. eds., pp. 353-355, l988.
19. Other works accepted for publication:
N/A
PROFESSIONAL
20. Funded Research Performed (include all grants received in the last five years, identifying
the principal investigator):
9/86-12/87
SWOG Subcontract #8645, $48,5l3. Southwest Oncology Group
Membership.
12/87
Principal Investigator for Adria Labs, Inc. "Epirubicin, Two-Dose levels vs.
Doxorubicin in the Treatment of Disseminated Carcinoma of the Breast" $5,ll2.
1/88
Co-Principal Investigator for Warner-Lambert Co. "Phase I- Study of Cl-908 3
Deazaguanine in Patients with Metastatic Cancer Refractory to Conventional
Therapy" $60,055.
2/88
Principal Investigator for Ciba-Geigy. "Comparative Study of CGP-23339A and
Etidronate Disodium in Treatment of Hypercalcemia of Malignancy Plus Open-Label
Humanitarian Extension" $20,000.
6/89
Principal Investigator for Ciga-Geigy. "Comparison of CGS l694 9A vs. Megestrol
Acetate in Post-Menopausal Women with Breast Carcinoma" $l20,000.
6/91
Principal Investigator for CIBA-GEIGY 19/2 Aredia vs. Placebo for the Prevention of
Skeletal Related Complications in Patients with Breast Cancer--Chemotherapy.
$151,000.
6/91
Principal Investigator for CIBA-GEIGY 18/3 Aredia vs. Placebo for the Prevention of
12
Skeletal Related Complications with Breast Cancer--Hormonal Therapy. $162,000.
11/93
Principal Investigator: Amgen NGN 0252, Phae I Trial of Cyclophosphamide
followed by 72 Hour Infusion of Topotecan in Patients with Solid Tumors.
11/15/93-11/14/95 Total Cost
$57,000.
8/94
Subcontractor (10% effort): Pain Management Skills for Minority Breast Cancer
Patients.
Department of Defense, Army Log #2551, Charles S. Cleeland, Ph.D.,
Principal Investigator: salary.8/15/94-8/14/98, $1,539,115Total Cost 8/15/94-8/14/95,
$293,347
Direct Cost
6/94
Subcontractor (10% effort): Cancer Pain Relief Skills for Minority Outpatients,
National Institutes of Health, CA 64766, Charles S. Cleeland, Ph.D., Principal
Investigator, salary.
6/1/94-5/31/98
Total Cost 6/1/94-5/31/95
Direct Cost
Principal Investigator: 1R01 CA64056-01. Breast Rescreening in Minority Women.
10/1/94-9/30/97
Total Annual Cost $280,000.00
21. Editorial responsibilities:
Richman, S.P. (consulting reviewer) Oncology Overview. Selected
abstracts on prognostic factors, chemotherapy and chemoimmunotherapy of malignant
melanoma. International Cancer Research Data Program. National Cancer Institute. May, l983.
Richman, S.P. (consulting reviewer) National Institute of Health Special Review Committee to
evaluate applications for adult AIDS clinical trial units (ACTUS), National Institute for Allergy
and Infectious Disease. October, 1991.
22. Professional and Honorary Organizations (member; officer; date):
Society memberships and offices
1.
2.
3.
4.
5.
American Association for Cancer Research
American College of Physicians
American Federation for Clinical Research
American Society of Clinical Oncology
Southern Medical Association
23. Honors and Awards:
13
Phi Beta Kappa
Alpha Omega Alpha
American Cancer Society Junior Faculty Award #32l
Fellowship, American College of Physicians
24. Post-Doctoral Fellowships:
1972 - 1974 Fellowship, Medical Oncology, Department of
Developmental Therapeutics, M.D. Anderson Hospital and Tumor
Institute.
25. Other Professional Activities (e.g., papers presented; performance; conference
Proceedings; seminar or conference panel member; etc.):
TEACHING
26. Teaching Awards Received: N/A
27. Thesis and Dissertation Advising/Post-doctoral student supervision (chairman or
committee member; topic; student name; date): N/A*
SERVICE
28. University Committee and Administrative Responsibilities:
Chief, Division of Medical Oncology
Acting Chairman, Dept. of Oncology
a.
Chairman, Scientific Committee, Kentucky Chapter, American College
of Physicians, l984.
b. Diagnostic Radiology Chairman - Search Committee, University of
Louisville.
c. Infection Control Committee - Norton Hospital, Louisville, Kentucky.
d. Medical Record Committee - Norton Hospital, Louisville, Kentucky.
e. American Cancer Society Institutional Research Grants Review Committee,
University of Louisville.
f. Radiotherapy Chairman - Search Committee, University of Miami.
g. UM/Jackson Hospital Cancer Committee
h. UMHC Executive Committee
i. UMHC Outpatient Care Committee
j. Cancer Center Clinical Research Committee
k. Sylvester Clinic Facility Planning Committee
l. Cancer Center Search Committee for Director
m. Dept of Urology Search Committee for Chairman
14
n.
o.
p.
q.
r.
s.
Cancer Control Search Committee for Director
Institutional Review Board (IRB)
Sylvester Cancer Center Executrive Committee
Sylvester Cancer Center Ethics Committee
Sylvester Cancer Center Scientific Steering Committee
Sylvester Cancer Center Quality Assurance Committee
29. Community Activities.
Leukemia Society Radio Telethon, l984.
15